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Chemotherapy
Concurrent chemotherapy was performed in 62 cases, neoadju-
vant chemotherapy in 25 cases, and adjuvant chemotherapy in 39
cases (Table 2). Chemotherapy regimens were DFP (docetaxel, 5 -
fluorouracil and cisplatin), FP (5- fluorouracil and cisplatin), tegafur/
gimeracil/oteracil potassium and nedaplatin plus 5- fluorouracil.
Outcome and toxicity analysis
Overall survival was defined as the period from the date of the
first RT fraction to the date of death. Survival was calculated with
Kaplan-Meier methods, and the significance of differences was
examined with the log-rank test. Cox’s proportional hazard model
was used for multivariate analysis. Differences were defined as
statistically significant at p0.05. Late radiation morbidity was
defined as a complication occurring more than 90 days after com-
pletion of RT. Grading of the morbidity was performed according to
the Radiation Therapy Oncology Group/European Organization
for Research and Treatment of Cancer late radiation morbidity
scoring schema. We used the Statistical Package for Social Science
(SPSS version 25 ; International Business Machines Corporation,
Armonk, NY, USA) for all analyses.
RESULTS
Figure 1 shows the local control rate for all patients and for each
stage. The 5-year local control rate of stage I, II, III, and IVA was
71.4%, 100%, 9.4%, and 38.5%, respectively. Univariate analysis
Table1. Characteristics of patients
Age
Median (range) 69 (44-94)
Sex
Male 57
Female 13
PS (ECOG)
0 27
1 36
2 7
Location
Cervical 7
Thoracic 56
Abdominal 3
Cervical - Thoracic 4
Pathological type
Squamous cell carcinoma 66
Adenocarcinoma 2
Unknown 2
T (UICC 8th)
1 16
2 8
3 14
4a 5
4b 27
N (UICC 8th)
0 24
1 20
2 21
3 5
Stage (UICC 8th)
 16
 9
 10
a 35
ECOG, Eastern Cooperative Oncology Group ; PS, performance status ;
UICC, Union for International Cancer Control
Table2. Setting of chemotherapy
n (%)
Neoadjuvant chemotherapy 25 (35.7)
Concurrent chemotherapy 62 (88.6)
Adjuvant chemotherapy 39 (55.7)
Fig.1
(a) Local control rate of all patients.
(b)Local control rate according to the stage.
a
b
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revealed that stage and neoadjuvant chemotherapy were signifi-
cant prognostic factors of local control (Table 3), although only
stage was a significant factor in multivariate analysis (Table 4).
Local recurrence occurred in 24 patients and lymph node recur-
rence within the irradiation field was observed in 8 patients. Lymph
node metastasis outside the irradiation field occurred in 12 cases
and distant metastasis was present in 20 cases. About half of the
cases were judged to be complete response after radiotherapy, and
only one salvage surgery was done.
The 5-year overall survival rate for stage I, II, III, and IVA was
81.3%, 71.4%, 0%, and 9.1%, respectively (Figure 2). Univariate
analysis of 5-year overall survival revealed that performance status,
clinical stage, and neoadjuvant chemotherapy were significant
prognostic factors of overall survival (Table 3), and these factors
remained significant in multivariate analysis (Table 5). No signifi-
cant relationship between radiation dose and clinical outcomes
was observed.
Table 6 shows clinical characteristics each of Stageand
Table3. Univariate analysis of 5-year local control rate and overall survival rate
Factor n 5-year LC rate (%) p-value 5-year OS rate (%) p-value
Age
< 69 34 67.0 0.224 38.3 0.582
69 36 40.0 31.8
Sex
Male 57 51.8 0.657 36.1 0.872
Female 13 60.6 30.8
PS
0-1 63 54.0 0.819 37.5 0.040
2-3 7 60.0 14.3
Stage
/ 25 79.3 <0.001 78.3 <0.001
/ 45 34.5 8.6
Location
Cervical 11 66.7 0.648 25.0 0.518
Thoracic-Abdominal 59 52.3 36.3
neoadjuvant chemotherapy
yes 25 27.3 0.01 12.5 <0.001
no 45 65.9 48.8
concurrent chemotherapy
yes 62 56.0 0.899 32.3 0.238
no 8 44.4 57.1
adjuvant chemotherapy
yes 39 54.8 0.589 26.9 0.301
no 31 53.3 44.1
Dose
< 60 Gy 29 51.8 0.497 41.0 0.109
60 Gy 41 55.4 30.9
Treatment period
< 44 days 16 58.6 0.830 46.7 0.216
44 days 54 52.1 31.5
LC, Local control ; OS, Overall survival
p-value was calculated using log-rank test.
Table4. Multivariate analysis of 5-year local control rate
Factor n p-value Hazard Ratio 95%CI
Stage
/ 25 0.003 1.00
/ 45 4.95 1.71-14.33
Neoadjuvant chemotherapy
yes 25 0.079 1.00
no 45 0.47 0.20-1.09
p-value was calculated using cox’s proportional hazard model.
The Journal of Medical Investigation Vol. 66 February 2019 101
Stage. There were more patients undergoing neoadjuvant
chemotherapy in Stage, although no significant difference
was observed in other factors. Univariate analysis of 5-year overall
survival revealed that performance status and neoadjuvant chemo-
therapy were significant prognostic factors in Stage, and
neoadjuvant chemotherapy was a significant prognostic factor in
Stage (Table 7). In multivariate analysis, performance status
and neoadjuvant chemotherapy were significant prognostic factors in
Stage(Table 8).
Late radiation morbidity of Grade 5 occurred in four cases ; three
patients died of radiation- induced lung injury and the other patient
died of hematemesis due to esophageal perforation. Fibrocystic
change of the lungs that showed a past history of interstitial pneu-
monia was observed on computed tomography before radiother-
apy in three patients who developed Grade 5 radiation-induced
lung injury.
DISCUSSION
The treatment results of RT for patients with esophageal cancer at
Tokushima University Hospital were similar to those of previous
reports (1, 11). The outcome of patients with advanced esophageal
cancer is still not satisfactory and reports indicate that there has
been no significant improvement in treatment outcomes of esopha-
geal cancer since the 2000s (9, 7) . In the present study, a history of
neoadjuvant chemotherapy was related to poor prognosis regard-
less of Stage. Possible reasons for this association include cases in
which surgery could not be performed because the tumor did not
shrink and crossover resistance of chemotherapy and radiother-
apy. The long-term results of NRG (National Surgical Adjuvant
Breast and Bowel Project, Radiation Therapy Oncology Group,
Gynecologic Oncology Group) Oncology Radiation Therapy
Oncology Group 0246 demonstrate promising efficacy of a selec-
tive surgical resection strategy in patients with esophageal cancer
after definitive concurrent chemoradiotherapy (12). In addition, a
report on preoperative chemoradiotherapy for resectable esophageal
cancer showed that chemoradiotherapy plus surgery significantly
reduced 3-year mortality, but postoperative mortality was signifi-
Fig.2
(a) Overall survival rate of all patients.
(b) Overall survival rate according to the stage.
Table5. Multivariate analysis of 5-year overall survival rate
Factor n p-value Hazard Ratio 95%CI
PS
0-1 63 0.008 1.00
2-3 7 3.44 1.38-8.55
Stage
/ 25 <0.001 1.00
/ 45 6.44 2.71-15.33
Neoadjuvant chemotherapy
yes 25 0.002 1.00
no 45 0.36 0.19-0.69
p-value was calculated using cox’s proportional hazard model.
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cantly increased by neoadjuvant chemoradiotherapy (13, 14).
However, these studies contain many cases of adenocarcinoma,
and it is unclear whether similar results will be obtained in Japan
where squamous cell carcinoma is dominant. A three-arm phase III
trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cis-
platin plus 5-FU versus RT plus CF as preoperative therapy for
locally advanced esophageal cancer (JCOG1109) (15) is being
conducted in Japan and the results are expected to lead to the
development of new treatment strategies for esophageal cancer.
In the present study, a different dose of 50.4 Gy/28 fractions or 60
Gy/30 fractions was delivered to a patient at random, and no
significant relationship between radiation dose and clinical outcomes
was observed. Further research is necessary to determine the
optimal dose of radiotherapy for esophageal cancer in Japan.
It has been previously reported that the occurrence of radiation-
induced lung injury is associated with radiation dose and volume of
lungs ; in particular, low-dose factors such as V20Gy (volume
percentage of the lungs that 20 Gy or greater are irradiated)
and V10 Gy are regarded as important (16-18). Guidelines of
JASTRO in Japan recommend that V20 Gy of the lungs should
be 30-35% or less ; however, the V20Gy of the lungs of three patients
who developed Grade 5 radiation- induced lung injury in the pre-
sent study was 23.4%, 18.3% and 17.3%, respectively. Except for
these three patients, interstitial pneumonia was not observed in
the pretreatment computed tomography. Thus, in patients with a
past history of interstitial pneumonia, even if the dose to the lungs is
low there is a possibility of causing severe radiation-induced lung
injury and strict attention should be paid to the indication of RT.
There are several limitations in the present study. It was a
retrospective study in a single institute and the number of cases
was small. There was no strict decision regarding radiation field,
and various regimens were used for chemotherapy.
In conclusion, the results of definitive radiotherapy for esopha-
geal cancer in stage I/II at Tokushima University Hospital were
similar to those of previous reports. However, treatment results of
the patients in stage III/IV were not satisfactory, and those who
could not undergo surgery after neoadjuvant chemotherapy had
the worst prognosis. The results of large-scale randomized trials in
Japan are expected to drive the development of new treatment
strategies to improve the prognosis of locally advanced esophageal
cancer.
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